+86-27-65522453 sales@sun-shinechem.com

Ellipticine

Catalog No.: 16122811
Cas No.: 519-23-3
Purity : 98% 
16122811 - Ellipticine | CAS 519-23-3

Catalog number : 16122811

CAS number : 519-23-3

Molecular Formula : C17H14N2 

Molecular Weight : 246.31 

Iupac Chemical Name : Ellipticine 

Smile : Cc1c2ccncc2c(c3c1[nH]c4c3cccc4)C

InChiKey : CTSPAMFJBXKSOY-UHFFFAOYSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsCCG-36483; CCG36483; CCG 36483; BRN-0221300; BRN0221300; BRN 0221300; DB-052047; K00071; LP00531; LS-133282; NSC 71795; NSC71795; NSC-71795; 
Molecular FormulaC17H14N2 
Molecular Weight246.31 
Appearancecrystalline solid 
Purity98% 
SolubilitySoluble in DMSO 
Storage3 years -20ºCpowder 
Shipping ConditionShipped under ambient temperature as non-hazardous chemical. 
SmileCc1c2ccncc2c(c3c1[nH]c4c3cccc4)C
InChiKeyCTSPAMFJBXKSOY-UHFFFAOYSA-N
InChiInChI=1S/C17H14N2/c1-10-14-9-18-8-7-12(14)11(2)17-16(10)13-5-3-4-6-15(13)19-17/h3-9,19H,1-2H3
MDLMFCD00010524
Coming soon.
Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor. Ellipticine is also a natural product, isolated in 1959 from the Australian evergreen tree of the Apocynaceae family. Ellipticine was found to be an extremely promising anticancer drug. The planar polycyclic structure was found to interact with DNA through intercalation, exhibiting a high DNA binding affinity (10(6) M(-1)). The presence of protonatable ring nitrogens distinguished ellipticine from other simple intercalators. Both monocationic and uncharged species were found to be present under physiological conditions. The positive charge stabilized the binding of ellipticine to nucleic acids, while the more lipophilic uncharged compound was shown to readily penetrate membrane barriers. The structural nature of these compounds offers a plausible basis for the implication of multiple modes of action, including DNA binding, interactions with membrane barriers, oxidative bioactivation and modification of enzyme function; most notably that of topoisomerase II and telomerase. ( Curr Med Chem Anticancer Agents. 2004 Mar;4(2):149-72 ). 

519-23-3 - Request Bulk Quote

×
519-23-3 - Request Bulk Quote
Change